Clinical Characteristics of Leukemia Patients
| Patient No. . | Sex . | Age . | Disease . | WBC (×109/L) . | Chemoresponsiveness . |
|---|---|---|---|---|---|
| 1 | F | 64 | AML-M4 | 130 | Stable resistant disease |
| 2 | F | 48 | AML-M4 | 135 | CR with SWOG8600 |
| 3 | M | 48 | AML-M5A | 46 | ED |
| 4 | M | 61 | AML-M5 | 158 | CR with araC/VP16/mitoxantrone |
| 5 | F | 39 | AML-M2 | 111 | CR with SWOG8600 |
| 6 | M | 45 | AML | 39 | CR with SWOG8600 |
| 7 | F | 46 | AML-M5B | 163 | ED |
| 8 | F | 69 | AML-M5 | 100 | CR with idarub./araC |
| 9 | M | 50 | AML | 203 | ED |
| 10 | M | 44 | AML-M5 | 46 | ED |
| 11 | F | 44 | AML-M4 | 139 | PR with SWOG8600 |
| 12 | F | 68 | AML-M4 | 74 | CR with araC/VP16/mitoxantrone |
| 13 | M | 58 | AML-M4 | 154 | ED |
| 14 | M | 47 | AML-M1 | 43 | CR with SWOG8600 |
| 15 | F | 37 | AML-M2 | 74 | NASS |
| 16 | M | 19 | AML-M2 | 64 | CR with SWOG8600 |
| 17 | M | 18 | AML-M4 | 87 | Stable resistant disease |
| 18 | M | 82 | AML-M4 | 56 | Received palliative hydrea |
| 19 | M | 60 | AML-M4 | 69 | CR with SWOG8600 |
| 20 | F | 22 | AML-M2 | 42 | NASS |
| 21 | F | 19 | AML-M5B | 79 | CR with SWOG8600 |
| 22 | F | 61 | AML-M2 | 21 | Stable resistant disease |
| 23 | M | 59 | AML-M4 | 76 | ED |
| 24 | M | 61 | AML-M0 | 170 | Stable resistant disease |
| 25 | M | 62 | AML-M4E | 63 | CR with SWOG8600 |
| 26 | M | 36 | AML-M2 | 165 | Stable resistant disease |
| 27 | M | 54 | AML-M7 | 26 | Stable resistant disease |
| 28 | M | 36 | AML-M5 | 119 | CR with SWOG8600 |
| 29 | M | 74 | AML-M5 | 118 | Received palliative hydrea |
| 30 | F | 51 | AML | 47 | Stable resistant disease |
| 31 | M | 63 | AML-M1 | 121 | Stable resistant disease |
| 32 | F | 75 | AML-M5 | 215 | CR with araC/VP16/mitoxantrone |
| 33 | M | 52 | AML-M2 | 196 | CR with SWOG8600 |
| 34 | F | 65 | AML-M4 | 151 | Stable resistant disease |
| 35 | M | 9 | AML-M5A | 150 | CR with VP16/mitoxantrone |
| 36 | F | 55 | AML-M1 | 129 | Stable resistant disease |
| 37 | M | 62 | AML-M1 | 79 | CR with SWOG8600 |
| 38 | M | 28 | AML-M2 | 38 | CR with SWOG8600 |
| 39 | M | 39 | AML-M2 | 83 | CR with SWOG8600 |
| 40 | M | 52 | AML-M1 | 199 | CR with araC/VP16/mitoxantrone |
| 41 | M | 23 | AML-M1 | 90 | CR with idarub./araC |
| 42 | M | 50 | AML-M2 | 44 | Stable resistant disease |
| 43 | M | 24 | AML-M2 | 68 | Stable resistant disease |
| 44 | F | 62 | AML | 295 | ED |
| 45 | F | 27 | AML-M0 | 120 | Stable resistant disease |
| 46 | M | 19 | AML-M5A | 43 | Stable resistant disease |
| 47 | F | 49 | AML(2°) | 30 | Stable resistant disease |
| 48 | M | 44 | AML-M2 | 211 | CR with SWOG8600 |
| 49 | M | 40 | AML-M1 | 212 | ED |
| 50 | M | 46 | AML-M2 | 53 | CR with SWOG8600 |
| 51 | M | 36 | ALL | 120 | Stable resistant disease |
| 52 | M | 36 | ALL | 501 | CR to VCR/Pred/Dauno/Lasp |
| 53 | M | 83 | PLL | 86 | Palliative steroids, leukapheresis |
| Patient No. . | Sex . | Age . | Disease . | WBC (×109/L) . | Chemoresponsiveness . |
|---|---|---|---|---|---|
| 1 | F | 64 | AML-M4 | 130 | Stable resistant disease |
| 2 | F | 48 | AML-M4 | 135 | CR with SWOG8600 |
| 3 | M | 48 | AML-M5A | 46 | ED |
| 4 | M | 61 | AML-M5 | 158 | CR with araC/VP16/mitoxantrone |
| 5 | F | 39 | AML-M2 | 111 | CR with SWOG8600 |
| 6 | M | 45 | AML | 39 | CR with SWOG8600 |
| 7 | F | 46 | AML-M5B | 163 | ED |
| 8 | F | 69 | AML-M5 | 100 | CR with idarub./araC |
| 9 | M | 50 | AML | 203 | ED |
| 10 | M | 44 | AML-M5 | 46 | ED |
| 11 | F | 44 | AML-M4 | 139 | PR with SWOG8600 |
| 12 | F | 68 | AML-M4 | 74 | CR with araC/VP16/mitoxantrone |
| 13 | M | 58 | AML-M4 | 154 | ED |
| 14 | M | 47 | AML-M1 | 43 | CR with SWOG8600 |
| 15 | F | 37 | AML-M2 | 74 | NASS |
| 16 | M | 19 | AML-M2 | 64 | CR with SWOG8600 |
| 17 | M | 18 | AML-M4 | 87 | Stable resistant disease |
| 18 | M | 82 | AML-M4 | 56 | Received palliative hydrea |
| 19 | M | 60 | AML-M4 | 69 | CR with SWOG8600 |
| 20 | F | 22 | AML-M2 | 42 | NASS |
| 21 | F | 19 | AML-M5B | 79 | CR with SWOG8600 |
| 22 | F | 61 | AML-M2 | 21 | Stable resistant disease |
| 23 | M | 59 | AML-M4 | 76 | ED |
| 24 | M | 61 | AML-M0 | 170 | Stable resistant disease |
| 25 | M | 62 | AML-M4E | 63 | CR with SWOG8600 |
| 26 | M | 36 | AML-M2 | 165 | Stable resistant disease |
| 27 | M | 54 | AML-M7 | 26 | Stable resistant disease |
| 28 | M | 36 | AML-M5 | 119 | CR with SWOG8600 |
| 29 | M | 74 | AML-M5 | 118 | Received palliative hydrea |
| 30 | F | 51 | AML | 47 | Stable resistant disease |
| 31 | M | 63 | AML-M1 | 121 | Stable resistant disease |
| 32 | F | 75 | AML-M5 | 215 | CR with araC/VP16/mitoxantrone |
| 33 | M | 52 | AML-M2 | 196 | CR with SWOG8600 |
| 34 | F | 65 | AML-M4 | 151 | Stable resistant disease |
| 35 | M | 9 | AML-M5A | 150 | CR with VP16/mitoxantrone |
| 36 | F | 55 | AML-M1 | 129 | Stable resistant disease |
| 37 | M | 62 | AML-M1 | 79 | CR with SWOG8600 |
| 38 | M | 28 | AML-M2 | 38 | CR with SWOG8600 |
| 39 | M | 39 | AML-M2 | 83 | CR with SWOG8600 |
| 40 | M | 52 | AML-M1 | 199 | CR with araC/VP16/mitoxantrone |
| 41 | M | 23 | AML-M1 | 90 | CR with idarub./araC |
| 42 | M | 50 | AML-M2 | 44 | Stable resistant disease |
| 43 | M | 24 | AML-M2 | 68 | Stable resistant disease |
| 44 | F | 62 | AML | 295 | ED |
| 45 | F | 27 | AML-M0 | 120 | Stable resistant disease |
| 46 | M | 19 | AML-M5A | 43 | Stable resistant disease |
| 47 | F | 49 | AML(2°) | 30 | Stable resistant disease |
| 48 | M | 44 | AML-M2 | 211 | CR with SWOG8600 |
| 49 | M | 40 | AML-M1 | 212 | ED |
| 50 | M | 46 | AML-M2 | 53 | CR with SWOG8600 |
| 51 | M | 36 | ALL | 120 | Stable resistant disease |
| 52 | M | 36 | ALL | 501 | CR to VCR/Pred/Dauno/Lasp |
| 53 | M | 83 | PLL | 86 | Palliative steroids, leukapheresis |
SWOG8600 induction is daunorubicin + cytosine arabinoside (normal or high dose).35
Abbreviations: ED, early death; CR, complete remission; PR, partial remission; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; PLI, prolymphocytic leukemia; NASS, not adequately assessed.